New melanoma vaccine reduces risk of cancer return and spread during trial

Hub Director Associate Professor Seth Cheetham appeared on 10 News to explain the Phase III trial result showing that a personalised mRNA cancer vaccine can reduce the risk of melanoma returning or spreading in patients at high risk of recurrence.

The segment covers how a vaccine is designed for one patient from the mutations in their own tumour, and what a result at this scale means for the treatments now moving into Australian trials.

Watch the report below.

← Back to all news